肺癌全身治疗的里程碑。
Milestones in the systemic treatment of lung cancer.
作者信息
Pirker Robert
机构信息
Department of Medicine I, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria.
出版信息
Memo. 2017;10(1):22-26. doi: 10.1007/s12254-017-0313-9. Epub 2017 Feb 6.
Abstract
Several milestones in the systemic treatment of lung cancer have been reached. Combination chemotherapy of small cell lung cancer was the first of these milestones. The establishment of palliative chemotherapy in patients with advanced non-small cell lung cancer and of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer was another important milestone. Targeted therapies with angiogenesis inhibitors, EGFR inhibitors, and ALK inhibitors also advanced treatment. The clinical introduction of immune checkpoint inhibitors was the latest milestone.
摘要
肺癌的系统治疗已取得了几个里程碑式的进展。小细胞肺癌的联合化疗是这些里程碑中的第一个。晚期非小细胞肺癌患者姑息化疗的建立以及完全切除的非小细胞肺癌患者辅助化疗的建立是另一个重要里程碑。血管生成抑制剂、表皮生长因子受体（EGFR）抑制剂和间变性淋巴瘤激酶（ALK）抑制剂的靶向治疗也推动了治疗的进步。免疫检查点抑制剂的临床应用是最新的里程碑。
相似文献
1
Milestones in the systemic treatment of lung cancer.肺癌全身治疗的里程碑。
Memo. 2017;10(1):22-26. doi: 10.1007/s12254-017-0313-9. Epub 2017 Feb 6.
2
The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer.血管生成抑制剂在免疫检查点抑制剂和靶向治疗时代的转移性非小细胞肺癌中的作用。
Curr Treat Options Oncol. 2019 Feb 18;20(3):21. doi: 10.1007/s11864-019-0617-6.
3
EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.表皮生长因子受体抑制剂作为表皮生长因子受体突变的可切除非小细胞肺癌的辅助治疗。
Lung Cancer. 2019 Oct;136:6-14. doi: 10.1016/j.lungcan.2019.08.001. Epub 2019 Aug 2.
4
Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations.晚期非小细胞肺癌：EGFR突变/ALK重排人群中的序贯治疗药物
Am Soc Clin Oncol Educ Book. 2019 Jan;39:e187-e197. doi: 10.1200/EDBK_237821. Epub 2019 May 17.
5
Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review.局部晚期和转移性非小细胞肺癌的系统治疗：综述。
JAMA. 2019 Aug 27;322(8):764-774. doi: 10.1001/jama.2019.11058.
6
[Combined Therapy with Targeted Drugs in Lung Cancer].[肺癌的靶向药物联合治疗]
Gan To Kagaku Ryoho. 2016 Apr;43(4):413-8.
7
Adjuvant treatment of non-small cell lung cancer: focus on targeted therapy.非小细胞肺癌的辅助治疗：聚焦靶向治疗。
J Thorac Dis. 2017 Oct;9(10):4064-4069. doi: 10.21037/jtd.2017.08.130.
8
Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer.非小细胞肺癌的分子机制和靶向治疗包括免疫疗法。
Curr Cancer Drug Targets. 2019;19(8):595-630. doi: 10.2174/1568009619666181210114559.
9
Systemic treatment of advanced non-small cell lung cancer: controversies and perspectives.晚期非小细胞肺癌的全身治疗：争议与展望
Memo. 2018;11(2):112-115. doi: 10.1007/s12254-018-0408-y. Epub 2018 May 18.
10
Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer.免疫检查点抑制剂在非小细胞肺癌治疗中的现状。
Korean J Intern Med. 2019 Jan;34(1):50-59. doi: 10.3904/kjim.2018.179. Epub 2018 Sep 3.
引用本文的文献
1
The prognostic significance of PD-1 and its ligands in non-small cell lung cancer.PD-1及其配体在非小细胞肺癌中的预后意义。
Turk Gogus Kalp Damar Cerrahisi Derg. 2024 Jan 29;32(1):84-92. doi: 10.5606/tgkdc.dergisi.2024.25394. eCollection 2024 Jan.
2
Roles of CCL2-CCR2 Axis in the Tumor Microenvironment.CCL2-CCR2 轴在肿瘤微环境中的作用。
Int J Mol Sci. 2021 Aug 8;22(16):8530. doi: 10.3390/ijms22168530.
3
Blockade of CCL2 enhances immunotherapeutic effect of anti-PD1 in lung cancer.CCL2的阻断增强了抗PD1在肺癌中的免疫治疗效果。
J Bone Oncol. 2018 Jan 8;11:27-32. doi: 10.1016/j.jbo.2018.01.002. eCollection 2018 Jun.
本文引用的文献
1
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.帕博利珠单抗对比化疗用于 PD-L1 阳性非小细胞肺癌。
N Engl J Med. 2016 Nov 10;375(19):1823-1833. doi: 10.1056/NEJMoa1606774. Epub 2016 Oct 8.
2
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.阿特珠单抗对比多西他赛用于治疗既往接受过治疗的非小细胞肺癌患者（POPLAR）：一项多中心、开放标签、2 期随机对照临床试验。
Lancet. 2016 Apr 30;387(10030):1837-46. doi: 10.1016/S0140-6736(16)00587-0. Epub 2016 Mar 10.
3
Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.第三代表皮生长因子受体酪氨酸激酶抑制剂用于晚期非小细胞肺癌
Curr Opin Oncol. 2016 Mar;28(2):115-21. doi: 10.1097/CCO.0000000000000260.
4
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.帕博利珠单抗对比多西他赛用于治疗后 PD-L1 阳性的、晚期非小细胞肺癌（KEYNOTE-010）：一项随机对照试验。
Lancet. 2016 Apr 9;387(10027):1540-1550. doi: 10.1016/S0140-6736(15)01281-7. Epub 2015 Dec 19.
5
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.纳武利尤单抗对比多西他赛治疗晚期非鳞状非小细胞肺癌
N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27.
6
The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification.2015 年世界卫生组织肺肿瘤分类：自 2004 年分类以来遗传、临床和放射学进展的影响。
J Thorac Oncol. 2015 Sep;10(9):1243-1260. doi: 10.1097/JTO.0000000000000630.
7
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.耐昔妥珠单抗联合吉西他滨和顺铂与吉西他滨和顺铂单药一线治疗局部晚期或转移性鳞状非小细胞肺癌患者（SQUIRE）：一项开放标签、随机、对照的 3 期临床试验。
Lancet Oncol. 2015 Jul;16(7):763-74. doi: 10.1016/S1470-2045(15)00021-2. Epub 2015 Jun 1.
8
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.纳武单抗与多西他赛治疗晚期鳞状细胞非小细胞肺癌的疗效比较
N Engl J Med. 2015 Jul 9;373(2):123-35. doi: 10.1056/NEJMoa1504627. Epub 2015 May 31.
9
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.阿法替尼治疗表皮生长因子受体抑制剂耐药的非小细胞肺癌
N Engl J Med. 2015 Apr 30;372(18):1689-99. doi: 10.1056/NEJMoa1411817.
10
Epidermal growth factor receptor-directed monoclonal antibodies in nonsmall cell lung cancer: an update.表皮生长因子受体导向的单克隆抗体在非小细胞肺癌中的应用进展
Curr Opin Oncol. 2015 Mar;27(2):87-93. doi: 10.1097/CCO.0000000000000162.
Zotero 插件